BEST UNLIMITED TURBO LONG CERTIFICATE - IPSEN | Market Closed - Euronext Paris 17:30:01 15/05/2024 BST | ||
| 2.025 EUR | -1.46% |
|
| Current month | +19.58% | ||
| 1 month | +44.44% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
IPSEN
| Date | Price | Change |
|---|---|---|
| 15/05/24 | 2.025 | -1.46% |
| 14/05/24 | 2.055 | +6.75% |
| 13/05/24 | 1.925 | -1.03% |
| 10/05/24 | 1.945 | 0.00% |
| 09/05/24 | 1.945 | +9.58% |
Real-time Euronext Paris
Last update May 15, 2024 at 05:30 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | IPSEN |
| Issuer | 
Société Générale
|
| 17Z1S | |
| ISIN | DE000SD47NA5 |
| Date issued | 01/04/2021 |
| Strike | 81.41 € |
| Maturity | Unlimited |
| Parity | 20 : 1 |
| Emission price | 0.21 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.745 € |
|---|---|
| Lowest since issue | 0.27 € |
| Spread | 0.03 € |
| Spread % | 1.48% |
Company Profile
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:
- oncology (75.2%);
- neuroscience (21.1%);
- rare diseases (3.7%).
At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide.
Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Sector
-
Consensus: Ipsen
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
121.4
EUR
Average target price
126.3
EUR
Spread / Average Target
+4.07%
- Stock Market
- Certificates
- 17Z1S Certificat
